Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | UBX-303061 |
| Synonyms | |
| Therapy Description |
UBX-303061 is a chimeric BTK degrader composed of an ligand for E3 ubiquitin ligase linked to a BTK-binding ligand, which induces proteasomal degradation of BTK, potentially leading to decreased growth of tumor cells overexpressing BTK (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| UBX-303061 | UBX303061|UBX 303061 | BTK inhibitor 38 | UBX-303061 is a chimeric BTK degrader composed of an ligand for E3 ubiquitin ligase linked to a BTK-binding ligand, which induces proteasomal degradation of BTK, potentially leading to decreased growth of tumor cells overexpressing BTK (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06590961 | Phase I | UBX-303061 | UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | POL | 1 |